In short: Reliable oncology supply comes from three things: buying through distributors with direct manufacturer relationships, keeping more than one approved brand available for critical molecules, and insisting on documented cold-chain delivery for biologics. Planning around clinic schedules and known shortage risks prevents most last-minute crises.
Buy close to the manufacturer
Every extra hand-off between manufacturer and hospital adds risk: of temperature excursions, of mixed-up batches, and of falsified product entering the chain. Distributors who buy directly from manufacturers can show clear provenance for every batch and usually get earlier notice of supply problems.
Keep more than one brand in play
For most high-volume oncology molecules — trastuzumab, bevacizumab, rituximab, bortezomib, pemetrexed and many more — India has several approved brands, including innovator products and biosimilars or generics. Approving more than one brand in your formulary means a single manufacturer’s shortage does not stop treatment.
It also lets patients and institutions choose on budget, which matters in a market where many patients pay out of pocket.
Insist on documented cold chain for biologics
Monoclonal antibodies and supportive-care biologics such as G-CSF should arrive with a temperature record. Ask your supplier to ship in validated shippers with a data logger, and check the record before accepting the consignment.
Plan around clinic days
Most oncology demand is predictable. A few habits make supply far smoother:
- Share your day-care schedule with your distributor so high-value biologics arrive the day before, not a week early.
- Agree a monthly rate contract for core molecules, with urgent top-ups for new patients.
- Ask your distributor to flag known manufacturer shortages early and propose approved alternatives.
This guide is general information for healthcare professionals, procurement teams and patients, not medical, legal or regulatory advice. Rules change; confirm with the relevant authority.